Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7382591 | 0.81 | EPHX2 (0.42) | EPHX2EPHX1ALDH1A1KDM4E | |
| SCHEMBL5567559 | 0.79 | EPHX1 (0.39) | EPHX2EPHX1ALDH1A1NPC1 | |
| SCHEMBL10271099 | 0.79 | EPHX2 (0.46) | EPHX2EPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL10155582 | 0.77 | EPHX2 (0.56) | EPHX2EPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL965099 | 0.77 | — | — | |
| SCHEMBL13801279 | 0.77 | LTA4H (0.38) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL2389051 | 0.76 | CTSL (0.33) | — | |
| SCHEMBL12522289 | 0.76 | EPHX2 (0.71) | EPHX2EPHX1 | |
| SCHEMBL10205154 | 0.74 | EPHX2 (0.45) | EPHX2EPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL10218754 | 0.74 | ALDH1A1 (0.59) | EPHX2EPHX1ALDH1A1CYP3A4KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | EPHX2 2553/4885EPHX1 2612/4885ALDH1A1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.